PAUL HWANGBO: Open Payments
NPI 1063024404 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,302 in 95 payments from 22 companies in 2025. Trend: 2023 $1,993 · 2024 $2,007 · 2025 $2,302
Food & beverage: $2,202Education: $100
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 16 | $392 |
| AstraZeneca Pharmaceuticals LP | 16 | $355 |
| Verona Pharma, Inc. | 9 | $259 |
| Viatris Specialty LLC | 5 | $143 |
| Grifols USA, LLC | 5 | $111 |
| Regeneron Healthcare Solutions, Inc. | 3 | $101 |
| SANOFI-AVENTIS U.S. LLC | 1 | $100 |
| Electromed, Inc. | 9 | $99 |
| Baxter Healthcare | 4 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $72 |
Products named: NUCALA, DUPIXENT, Ohtuvayre, TEZSPIRE, YUPELRI, Prolastin-C Liquid, TRELEGY ELLIPTA, FASENRA.
Industry payments across GA — which companies pay providers there.
